Minimal B Cell Extrinsic IgG Glycan Modifications of Pro- and Anti-Inflammatory IgG Preparations in vivo

Schaffert A, Hanic M, Novokmet M, Zaytseva O, Kristic J, Lux A, Nitschke L, Peipp M, Pezer M, Hennig R, Rapp E, Lauc G, Nimmerjahn F (2020)

Publication Type: Journal article

Publication year: 2020

Journal

Book Volume: 10

Article Number: 3024

DOI: 10.3389/fimmu.2019.03024

Abstract

Select residues in the biantennary sugar moiety attached to the fragment crystallizable of immunoglobulin G (IgG) antibodies can modulate IgG effector functions. Thus, afucosylated IgG glycovariants have enhanced cytotoxic activity, whereas IgG glycovariants rich in terminal sialic acid residues can trigger anti-inflammatory effects. More recent evidence suggests that terminal α2,6 linked sialic acids can be attached to antibodies post IgG secretion. These findings raise concerns for the use of therapeutic antibodies as they may change their glycosylation status in the patient and hence affect their activity. To investigate to what extent B cell extrinsic sialylation processes modify therapeutic IgG preparations in vivo, we analyzed changes in human intravenous IgG (IVIg) sialylation upon injection in mice deficient in B cells or in mice lacking the sialyltransferase 1, which catalyzes the addition of α2,6 linked sialic acid residues. By performing a time course of IgG glycan analysis with HILIC-UPLC-FLR (plus MS) and xCGE-LIF our study suggests that therapeutic IgG glycosylation is stable upon injection in vivo. Only a very small fraction of IgG molecules acquired sialic acid structures predominantly in the Fab- but not the Fc-portion upon injection in vivo, suggesting that therapeutic antibody glycosylation will remain stable upon injection in vivo.

Authors with CRIS profile

Involved external institutions

Genos Glycoscience Research Laboratory Croatia (HR) glyXera GmbH Germany (DE) Christian-Albrechts-Universität zu Kiel Germany (DE)

How to cite

APA:

Schaffert, A., Hanic, M., Novokmet, M., Zaytseva, O., Kristic, J., Lux, A.,... Nimmerjahn, F. (2020). Minimal B Cell Extrinsic IgG Glycan Modifications of Pro- and Anti-Inflammatory IgG Preparations in vivo. Frontiers in Immunology, 10. https://doi.org/10.3389/fimmu.2019.03024

MLA:

Schaffert, Anja, et al. "Minimal B Cell Extrinsic IgG Glycan Modifications of Pro- and Anti-Inflammatory IgG Preparations in vivo." Frontiers in Immunology 10 (2020).

BibTeX: Download